GFAP and glioma: Transgenic GFAP-EGFRvIII; GFAP-Cre/RictorloxP/loxP mice exhibited a marked reduction in overall survival with 50% of animals developing gliomas by 4–6 weeks and all of the mice succumbing by 18 weeks.